Assessments

FOR COVID-19 TECHNOLOGIES

The Department of Health – Health Technology Assessment Unit (HTAU) has conducted rapid reviews on various health technologies related to COVID-19 to support the evidence-informed decisions of policymakers.

You may access the evidence summary and the rapid review report by clicking the link provided for each health technology.

Important note: As evidence-gathering on the different facets of COVID-19 is ongoing and rapidly evolving, regular scoping for evidence and updating of recommendations are strongly advised; hence, the information stated in these reviews may be revised as new evidence emerges.

Assessments

Lapatinib in treatment of HER2-positive breast cancer patients

Use of Rapid Antigen Test Kits for the Diagnosis of COVID-19 (April 2021 Assessment)

Janssen Ad26.COV2.S (COVID-19) Vaccine for the prevention of COVID-19

Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the prevention of COVID-19

SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the prevention of COVID-19

COVID-19 Vaccine (ChAdOx1-S [recombinant]) (COVID-19 Vaccine AstraZeneca) for the prevention of COVID-19

[ANNOUNCEMENT] HTA COUNCIL RELEASES ITS PRELIMINARY RECOMMENDATION ON THE FINANCING OF 34 MEDICAL DEVICES TO BE INCLUDED IN Q1 UPDATE OF THE PEMDL

[ANNOUNCEMENT] HTA COUNCIL RELEASES ITS PRELIMINARY RECOMMENDATION ON THE FINANCING OF DOACS FOR NONVALVULAR ATRIAL FIBRILLATION

[ANNOUNCEMENT] HTA COUNCIL RELEASES ITS PRELIMINARY RECOMMENDATION ON THE NON-FINANCING OF CEREBROLYSIN FOR POST ISCHEMIC STROKE